A biosimilar is a biologic drug built to match an existing, already-approved biologic closely enough to substitute for it, and its cold chain starts from the same physical requirements as the original. If the reference product needs 2-8°C refrigeration from manufacture to injection, the biosimilar version needs exactly the same, because biosimilarity is about matching the originator's clinical profile, not about relaxing how the protein has to be handled. Nothing about being a biosimilar makes the molecule any less sensitive to heat, freezing or agitation.
It sits in the knowledge base alongside the storage and packaging topics that any biologic, originator or biosimilar, depends on to reach a patient intact.
Copying the clinical profile, not the packaging budget
A biosimilar maker has to demonstrate that its product behaves the same as the reference biologic across stability, purity and clinical effect, which locks in the same refrigerated storage band, the same handling sensitivity and often close to the same shelf life as the original. What a biosimilar maker does not inherit automatically is the originator's logistics infrastructure or its established distribution relationships, so a new entrant is frequently building or contracting the cold chain from close to scratch for a product that has to meet the same physical bar the incumbent already cleared years earlier.
Margins are tighter than the originator ever had to manage
Biosimilars exist to compete on price against an established, already-profitable originator, and that competitive pressure lands directly on every part of the supply chain, logistics included. A cold chain built around premium overnight courier lanes and generous packaging margins, the kind an originator could absorb early in its life, is a harder cost structure for a biosimilar competing mainly on price to sustain. That pushes biosimilar distribution toward leaner packaging choices, consolidated shipping lanes and negotiated carrier contracts, without ever loosening the temperature and handling requirements the product itself still carries.
A crowded entry, then a shakeout
When a biosimilar's reference product comes off patent, several competing biosimilar versions often launch into the same market close together, each needing to stand up its own cold chain distribution at once rather than growing into demand gradually the way an originator did. That crowded entry period is the busiest and most logistically strained phase for a biosimilar's supply chain, and it typically eases once a smaller number of versions settle into the market and volumes per manufacturer become more predictable. Distributors serving that category plan capacity for the surge at launch, not just the steadier volume that follows.
Hospital and pharmacy channels, not a single distribution model
Biosimilars move through the same two broad channels as any other injectable biologic: hospital and infusion-center distribution for products administered under clinical supervision, and retail or specialty pharmacy distribution for products a patient self-injects at home. The two channels carry different cold chain demands. Hospital distribution deals in bulk, refrigerated storage inside a controlled facility with staff trained to handle it. Pharmacy and patient channels hand an insulated shipper or a small refrigerated pack to someone with no cold chain training at all, the same patient-handling gap that shows up with insulin and other self-administered biologics.
The same verification bar as the original
Nothing about a biosimilar justifies a shortcut on monitoring or verification. A dose that has been mishandled is just as much a clinical risk as a mishandled originator dose, and regulators evaluate a biosimilar's cold chain against the same standards as any other biologic, not a relaxed one. Shipments still travel with the same temperature data loggers and the same excursion tolerances the reference product carries. The commercial pressure that biosimilars face changes how tightly a distributor manages cost. It does not, and should not, change the temperature band or the verification a shipment needs before it reaches a patient.
Formulary switching multiplies the packaging variables
Hospitals and payers frequently switch which biosimilar brand they stock for a given molecule, so the same clinical indication can be filled by a different manufacturer's vials from one procurement cycle to the next. Each brand runs its own stability studies, its own container closure system and its own excursion tolerance under its own regulatory filing, even though the molecule they carry is clinically interchangeable. A pharmacy or hospital cold store cannot treat that as one universal biosimilar profile; it has to keep brand-specific handling notes on file and update them every time a formulary switch brings in a new manufacturer's product.
That churn falls hardest on smaller hospital pharmacies and infusion centers, which may stock two or three competing biosimilar brands at once during a transition period rather than a single settled product. Staff training and cold-storage labeling have to track which vial belongs to which manufacturer's protocol, a burden the originator's single, stable supply chain never had to carry.